Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. The company is headquartered in Omaha, Nebraska.
52W High
$2.45
52W Low
$0.11
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
2.51
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
2.80
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
24.45%
Institutions (25–75% balanced)
1.43%
Shares Outstanding
61,374,000
Float
48,221,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-0.46
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-2.50%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
-0.1151
Previous
-0.1246
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025